知名功效护肤品牌入局注射医美

Core Viewpoint - The entry of Waldencast Acquisition Corp. into the injectable aesthetic market through the acquisition of Novaestiq Corp. signifies a strategic expansion for the company, particularly for its brand Obagi Medical, into a rapidly growing segment of the beauty industry [1][3][4]. Group 1: Acquisition Details - Waldencast has acquired Novaestiq, gaining exclusive rights to sell the Saypha® series of hyaluronic acid injection gels in the U.S. [1][7]. - The transaction allows Obagi Medical to extend its product offerings from professional skincare to dermal filler treatments, with the U.S. dermal filler market projected to reach $2 billion by 2029 [3][4]. - The specific terms of the acquisition were not disclosed, but it marks Waldencast's first foray into the injectable aesthetic sector [3][4]. Group 2: Market Context - The U.S. is the largest market for injectable aesthetics, accounting for approximately 20.8% of global treatment procedures, with a significant increase in hyaluronic acid treatments [18][19]. - The competition in the injectable aesthetic market is intensifying, with major beauty brands like L'Oréal and Shiseido also entering the space [22][24]. - The global injectable market is primarily dominated by hyaluronic acid and botulinum toxin, with hyaluronic acid showing a 5.2% year-on-year growth [18][19]. Group 3: Brand Performance - Obagi Medical has experienced rapid growth since its entry into the Chinese market in 2018, with annual revenue growth rates exceeding 400% from 2019 [15]. - However, due to the separation of its Chinese operations during the 2022 merger, Obagi's performance in China has declined significantly [15]. - In the latest quarter, Obagi Medical reported a 7.1% year-on-year revenue increase, contrasting with a decline in its sister brand Milk Makeup, which saw a 15.1% drop [17]. Group 4: Future Outlook - The potential for Saypha® in the injectable market is promising, but it will face substantial competition as more players enter the field [19][26]. - The emergence of new materials for injectable aesthetics, such as agarose and hydroxyapatite, indicates a diversification in product offerings, which could intensify competition [26][27]. - Success in the injectable aesthetic market will depend on Obagi's ability to establish unique technological advantages and maintain a strong brand presence [27].